D

    Daxor Corporation (DXR)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $10.36
    +0.16 (+1.57%)

    Market Cap: $59.55M

    Last updated: Aug 31, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    43%(3/7)
    Avg Surprise
    -605.36%
    Streak
    2 Q

    Upcoming Estimates

    Mar 31, 2026
    EPS Consensus$-0.11
    Range$-0.11 - $-0.11
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.11+0.0%
    60d ago$-0.11+0.0%
    30d ago$-0.11+0.0%
    7d ago$-0.11+0.0%
    Current$-0.11
    Revenue Consensus
    $2M
    Range$2M - $2M
    1 analysts
    Jun 30, 2026
    EPS Consensus$-0.03
    Range$-0.03 - $-0.03
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.03+0.0%
    60d ago$-0.03+0.0%
    30d ago$-0.03+0.0%
    7d ago$-0.03+0.0%
    Current$-0.03
    Revenue Consensus
    $3M
    Range$3M - $3M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26EST
    		-$-0.03---
    Mar 26EST
    		-$-0.11---
    Jun 25
    		$-0.07$0.00N/AMiss-
    Mar 25
    		$0.00$0.00N/ABeat-
    Dec 24
    		$0.43$0.00N/ABeat-
    Sep 24
    		$0.00$0.00N/ABeat-
    Jun 24
    		$0.00$0.00N/ABeat-
    Mar 24
    		$0.00$0.00N/ABeat-
    Dec 23
    		$0.00$0.00N/ABeat-100.0%
    Sep 23
    		$0.00$0.00N/ABeat-
    Jun 23
    		$0.00$0.00N/ABeat+100.0%
    Mar 23
    		$0.00$0.00N/ABeat-
    Dec 22
    		$1.54$0.00N/ABeat-1.3%
    Sep 22
    		$0.00$0.00N/ABeat-
    Jun 22
    		$-0.45$0.00N/AMiss-18.4%
    Mar 22
    		$0.00$0.00N/ABeat+100.0%
    Dec 21
    		$1.56$0.00N/ABeat+239.1%
    Sep 21
    		$0.00$0.00N/ABeat-100.0%
    Jun 21
    		$-0.38$0.00N/AMiss+58.2%
    Mar 21
    		$-0.19$0.00N/AMiss+57.9%
    Dec 20
    		$0.46$0.04+1050.00%Beat+355.6%
    Sep 20
    		$0.23$0.04+471.00%Beat+283.7%
    Jun 20
    		$-0.91$0.04-2375.00%Miss-1616.7%
    Mar 20
    		$-0.46$0.04-1240.50%Miss-2381.0%
    Dec 19
    		$-0.18$0.02-1000.00%Miss-350.0%
    Sep 19
    		$-0.12$0.01-1343.00%Miss-
    Jun 19
    		$0.06$0.02+200.00%Beat+150.0%
    Mar 19
    		$0.02$0.00N/ABeat-
    Dec 18
    		$-0.04$0.00N/AMiss+55.6%
    Sep 18
    		$0.00$0.00N/ABeat+100.0%
    Jun 18
    		$-0.12$0.00N/AMiss-140.0%
    Mar 18
    		$0.00$0.00N/ABeat-
    Dec 17
    		$-0.09N/AN/ABeat-
    Jun 17
    		$-0.16$0.00N/AMiss-
    Dec 16
    		$-0.05$0.00N/AMiss-

    Dividends

    Dividend Metrics

    Yield0.00%
    Annual/Share$0.00
    Payout Ratio0.00%
    Frequency1
    No dividend payments in the selected period.
    View DXR's full dividend history

    Key Metrics

    Valuation
    P/E Ratio7.14EV/EBITDAN/A
    Price/FCF-30.03xFCF Yield-3.33%
    Profitability
    Profit Margin34359.00%Operating Margin-9661.00%
    ROE22.50%ROIC1.07%
    Financial Health
    Debt/Equity0.00xInterest Coverage7.30x
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    Beta0.27Avg Volume2.51K
    52-Week High$14.7652-Week Low$8.56

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$10.11
    SMA 20$10.23
    SMA 50$10.35
    SMA 200$11.31
    EMA 10$10.14
    EMA 20$10.21
    EMA 50$10.31
    EMA 200$10.70

    MACD

    Line: -0.09Signal: -0.09Hist: -0.00

    ADX

    ADX: 15.7+DI: 23.9-DI: 28.9

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down88.0
    PSAR$9.57

    Bollinger Bands

    Upper Band$10.66
    Lower Band$9.80
    %B Position840%(Upper)
    Band Width0.65

    RSI (14-Day)

    Neutral
    52.4

    Momentum Oscillators

    Stoch %K49.9
    Stoch %D41.8
    Williams %R-24.3
    ROC (10d)1.5%
    Momentum0.16
    CCI (20d)-1.8
    MFI (14d)53.7

    Volatility Measures

    ATR (14d)$0.36(3.5%)
    StdDev (20d)0.21
    Hist Vol36.1%(Moderate)

    Volume Flow

    VWAP$10.21
    OBV1.4M
    AD Line94.0K
    CMF (20d)0.070

    Volume Metrics

    Avg Vol (20d)2.6K
    Vol Ratio0.3x(Low)
    VWMA (20d)$10.09

    Pivot Points

    R3$11.63
    R2$11.13
    R1$10.66
    Pivot Point$10.16
    S1$9.69
    S2$9.19
    S3$8.72

    Advanced Oscillators

    TSI-7.67
    Ultimate Osc58.2
    KST-33.40

    Financial Data

    QuarterDec 2025Jun 2025Dec 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022
    Total Revenue$131,846$18,348$695,307$71,756$35,878$82,448$41,224$80,974$40,487$96,398$48,199$135,244
    Cost of Revenue$236,481$78,202$74,644$90,239N/A$-4,636N/A$439,316N/A$726,183N/A$360,890
    Gross Profit$-104,635$18,348$620,663$71,756$35,878$82,448$41,224$80,974$40,487$96,398$48,199$135,244
    Operating Expenses$-9,647,456$287,847$1.23M$369,306$184,653$503,016$1.62M$3.07M$1.54M$6.94M$3.47M$1.92M
    R&D$0$0$0$0$0$0$0$0$0$0$0$0
    SG&A$0$82,633$200,575$93,610$46,805$128,686$64,343$436,048$218,024$721,442$360,721$364,044
    Operating Income$9.54M$-269,499$2.21M$-297,550$-148,775$3.06M$-210,793$-366,458$-183,229$-624,208$-312,104$-235,526
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$3,346$12,617$38,170$2.96M$666,634$4,636$0$44,466$1.34M$45,267$0$1.58M
    Income Before Tax$9.54M$-369,701$2.17M$-3,261,634$-815,409$3.32M$1.66M$-3,037,182$-1,518,591$6.99M$3.50M$-1,812,498
    Income Tax Expense$0$0$0$-1,630,816$0$3.74M$1.87M$-2,670,724$-1,335,362$7.61M$3.81M$-1,576,972
    Net Income$9.54M$-369,701$2.17M$-1,630,818$-815,409$3.32M$1.66M$-3,037,182$-1,518,591$6.99M$3.50M$-1,812,498
    EBITDA$9.54MN/A$3.34M$-1,283,062$1,643$3.06M$1.87M$-2,992,710$-1,335,362$3.81M$3.81M$-788,486
    EBITN/AN/A$2.21M$-1,583,898$-148,775$2.85M$1.66M$-3,175,939$-1,518,591$-3,183,210$3.50M$-874,551
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DXR

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    N/A
    Obligations YoY
    -100.0%
    Active Awards
    1
    New Awards (TTM)
    0
    Avg Remaining Term
    24.9 mo

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Daxor Corp (DXR) Stock News Today

    This article provides the latest stock news for Daxor Corp (DXR) from TradingKey. It shows the company's current stock price, market capitalization, P/E ratio, and highlights that more news and updates are expected soon. The page serves as a hub for financial information regarding DXR.

    TradingKey•8/10/26•
    Neutral

    Daxor Corp (DXR) Earnings Forecast: Future EPS & Revenue Growth Estimates

    This article provides an earnings forecast for Daxor Corp (DXR), detailing analyst ratings and price targets. Based on input from two analysts, the consensus is a "Buy" trend with a target price of $22.50, representing a potential upside of 113.88%. The highest forecast is $25.00 and the lowest is $22.00.

    TradingKey•8/8/26•
    Somewhat-Bullish

    Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

    Daxor Corporation (Nasdaq: DXR) announced the launch of a new outpatient Blood Volume Analysis (BVA) program in eastern Kansas, expanding its presence in Midwestern outpatient care. This initiative utilizes Daxor's turnkey ezBVA Lab send-out model, offering quick and accurate blood volume measurements without requiring capital equipment from healthcare facilities. The service aims to provide clinicians with objective data for fluid management, optimizing patient outcomes, preventing readmissions, and lowering healthcare system costs.

    Yahoo Finance•7/30/26•
    Bullish

    Daxor Corporation Launches Outpatient Blood Volume Analysis Program at Kansas Healthcare Facility

    Daxor Corporation has launched a new outpatient Blood Volume Analysis (BVA™) program at a major healthcare facility in eastern Kansas, aiming to enhance precision diagnostics and patient outcomes in the Midwest. This initiative utilizes the ezBVA Lab send-out model, allowing healthcare providers to obtain highly accurate blood volume metrics within 24 hours without significant capital investment. The program seeks to improve patient care by providing objective data for fluid management, thereby reducing hospital readmissions, especially for conditions like heart failure.

    Quiver Quantitative•7/30/26•
    Bullish

    A Kansas Facility Gets Daxor Blood-Volume Results in 24 Hours

    Daxor Corporation has launched an outpatient Blood Volume Analysis (BVA) program in eastern Kansas, providing 98% accurate blood volume measurements within 24 hours. This service uses a CLIA-certified send-out model, eliminating the need for capital equipment at outpatient practices and aiming to improve patient outcomes by replacing subjective fluid assessment with objective metrics. The expansion seeks to reduce hospital readmissions and optimize decongestion strategies for patients.

    Stock Titan•7/30/26•
    Neutral

    Frequently Asked Questions About DXR

    Does DXR pay dividends?
    Daxor Corporation (DXR) has a dividend payment track record. See the DXR dividend history page for its current payment status, yield, and streaks.
    What is DXR's P/E ratio?
    Daxor Corporation has a price-to-earnings (P/E) ratio of 7.14.
    What is DXR's market cap?
    Daxor Corporation (DXR) has a market capitalization of $59.55M with a current stock price of $10.36.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In